[The inhibitory effect of the synthetic leu-enkephalin analog dalargin on carcinogenesis].
Dalargin, an opioid peptide (Tyr-D-Ala-Gly-Phe-Leu-Arg), was shown to significantly inhibit the carcinogenic effect of 50 mg/kg body weight nitrosomethylurea given as single i. v. infection. The treatment was followed by an increase in the tumor latency period. Moreover, the overall incidence of tumors decreased by 20% whereas that of malignant neoplasms and breast adenocarcinoma--by 33 and 27%, respectively. Pronounced inhibitory effect of dalargin on hematopoietic tumor induction was identified, too.
Anisimov
V N
VN
Bortkevich
S M
SM
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004354:Drug Screening Assays, Antitumor; D004743:Enkephalin, Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives*; D005260:Female; D008770:Methylnitrosourea; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D051381:Rats; D013565:Sympatholytics / Q000627:therapeutic use; D013997:Time Factors
D000970:Antineoplastic Agents; D013565:Sympatholytics; D004743:Enkephalin, Leucine; D016308:Enkephalin, Leucine-2-Alanine; D008770:Methylnitrosourea; C040996:enkephalin-Leu, Ala(2)-Arg(6)-
Tormoziashchee vliianie sinteticheskogo analoga leĭénkefalina dalargina na kantserogenez.